Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall

Executive Summary

Shares in Mast Therapeutics dropped by more than 80% upon news that a Phase III trial of its lead product vepoloxamer in sickle cell disease had failed.

Advertisement

Related Content

Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
Deal Watch: J.P. Morgan Brings Continued Brisk Pace Of Transactions
Novartis Buys Selexys As Competitors Stumble In Sickle Cell
Modus's Intended IPO to Spur Sickle Cell Drug R&D
Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness
Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel